Myriad Genetics, Inc. (MYGN)
4.15
-0.20
(-4.60%)
USD |
NASDAQ |
Oct 16, 13:09
Myriad Genetics SG&A Expense (TTM) : 539.90M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 539.90M |
| March 31, 2026 | 537.70M |
| December 31, 2025 | 537.60M |
| September 30, 2025 | 551.80M |
| June 30, 2025 | 552.00M |
| March 31, 2025 | 558.20M |
| December 31, 2024 | 563.10M |
| September 30, 2024 | 570.00M |
| June 30, 2024 | 567.00M |
| March 31, 2024 | 562.80M |
| December 31, 2023 | 573.90M |
| September 30, 2023 | 575.00M |
| June 30, 2023 | 569.40M |
| March 31, 2023 | 555.80M |
| December 31, 2022 | 514.70M |
| September 30, 2022 | 495.70M |
| June 30, 2022 | 545.40M |
| March 31, 2022 | 553.10M |
| December 31, 2021 | 588.00M |
| September 30, 2021 | 567.90M |
| June 30, 2021 | 520.60M |
| March 31, 2021 | 521.40M |
| June 30, 2020 | 511.40M |
| March 31, 2020 | 553.80M |
| December 31, 2019 | 561.50M |
| Date | Value |
|---|---|
| September 30, 2019 | 561.10M |
| June 30, 2019 | 555.50M |
| March 31, 2019 | 518.20M |
| December 31, 2018 | 485.50M |
| September 30, 2018 | 457.70M |
| June 30, 2018 | 435.00M |
| March 31, 2018 | 444.60M |
| December 31, 2017 | 458.80M |
| September 30, 2017 | 471.70M |
| June 30, 2017 | 476.40M |
| March 31, 2017 | 445.60M |
| December 31, 2016 | 414.00M |
| September 30, 2016 | 384.50M |
| June 30, 2016 | 359.10M |
| March 31, 2016 | 365.30M |
| December 31, 2015 | 366.08M |
| September 30, 2015 | 367.97M |
| June 30, 2015 | 366.91M |
| March 31, 2015 | 353.76M |
| December 31, 2014 | 350.11M |
| September 30, 2014 | 335.26M |
| June 30, 2014 | 327.10M |
| March 31, 2014 | 314.30M |
| December 31, 2013 | 291.27M |
| September 30, 2013 | 272.99M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Natera, Inc. | 1.255B |
| Sera Prognostics, Inc. | 24.17M |
| BioRestorative Therapies, Inc. | 5.181M |
| CareDx, Inc. | 247.69M |
| Exagen, Inc. | 48.45M |